Non-Hodgkin Lymphoma | Specialty

Novel Approaches Gain Ground in Diffuse Large B-Cell Lymphoma

February 28th 2020

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

Dr. Goodman on Contributing Factors to the Lack of Development in PTCL Treatment

February 28th 2020

Aaron Goodman, MD, discusses factors that have contributed to the lack of treatment development in peripheral T-cell lymphoma.

NICE Recommends Lenalidomide/Rituximab for Follicular Lymphoma

February 28th 2020

The United Kingdom’s National Institute for Health and Care Excellence has recommended the combination of lenalidomide and rituximab as a treatment option for adult patients with grade 1 to 3A previously treated follicular lymphoma.

NICE Rejects Polatuzumab Vedotin Combo in Relapsed/Refractory DLBCL

February 27th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend polatuzumab vedotin plus rituximab and bendamustine for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma who cannot undergo hematopoietic stem cell transplant.

Expert Highlights Emergence of Mosunetuzumab in Non-Hodgkin Lymphoma

February 26th 2020

Stephen J. Schuster, MD, discusses promising findings and next steps for mosunetuzumab in patients with relapsed/refractory non-Hodgkin lymphoma.

Optimal Treatment Selection Needed in Advanced Follicular Lymphoma

February 26th 2020

Benjamin Heyman, MD, discusses frontline and maintenance therapy options, novel targeted approaches, and the expanding role of minimal residual disease in patients with follicular lymphoma.

CAR-T Leads Advances Across Lymphomas, But Further Research Needed

February 25th 2020

Dimitrios Tzachanis, MD, PhD, discusses updates and remaining questions with CAR T-cell therapy.

Novel Approaches Under Exploration Across Lymphoma Subtypes

February 24th 2020

Erin Reid, MD, discusses the treatment advances across lymphomas and the remaining questions that need to be answered with further research.

Future Directions and Unmet Needs for Treatment of DLBCL

January 30th 2020

Emerging Agents in the Management of R/R DLBCL

January 30th 2020

L-MIND Trial in Relapsed/Refractory DLBCL

January 30th 2020

Future Directions of CAR T Therapy in R/R DLBCL

January 30th 2020

R/R DLBCL: CAR T Therapy and Immune Checkpoint Inhibition

January 30th 2020

Safety and Efficacy of CAR T Therapy in R/R DLBCL

January 30th 2020

Use of CAR T Therapy in R/R DLBCL

January 30th 2020

Treatment Alternatives to Chemotherapy in R/R DLBCL

January 30th 2020

Management of Relapsed/Refractory DLBCL

January 30th 2020

Role of CNS Prophylaxis in DLBCL

January 30th 2020

Optimization of PET Scans and Determining Relapse in DLBCL

January 30th 2020

Comorbidities and Role of R-CHOP in DLBCL

January 30th 2020